BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32852366)

  • 1. Are Some Randomized Clinical Trials Impossible?
    Rios JJ; Richards BS; Stevenson DA; Oberlander B; Viskochil D; Gross AM; Dombi E; Widemann BC; Plotkin SR; May CJ; Ullrich NJ; Goldstein RY; Jain V; Schorry EK;
    J Pediatr Orthop; 2021 Jan; 41(1):e90-e93. PubMed ID: 32852366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved union and bone strength in a mouse model of NF1 pseudarthrosis treated with recombinant human bone morphogenetic protein-2 and zoledronic acid.
    Deo N; Cheng TL; Mikulec K; Peacock L; Little DG; Schindeler A
    J Orthop Res; 2018 Mar; 36(3):930-936. PubMed ID: 28767180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
    El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
    J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. rhBMP-2 and Intramedullary Fixation in Congenital Pseudarthrosis of the Tibia.
    Richards BS; Anderson TD
    J Pediatr Orthop; 2018 Apr; 38(4):230-238. PubMed ID: 27261960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells.
    El-Hoss J; Sullivan K; Cheng T; Yu NY; Bobyn JD; Peacock L; Mikulec K; Baldock P; Alexander IE; Schindeler A; Little DG
    J Bone Miner Res; 2012 Jan; 27(1):68-78. PubMed ID: 21956219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of rhBMP-2 for the treatment of congenital pseudarthrosis of the tibia: a case series.
    Richards BS; Oetgen ME; Johnston CE
    J Bone Joint Surg Am; 2010 Jan; 92(1):177-85. PubMed ID: 20048110
    [No Abstract]   [Full Text] [Related]  

  • 7. Bone morphogenetic protein 7 in the treatment of congenital pseudarthrosis of the tibia.
    Fabeck L; Ghafil D; Gerroudj M; Baillon R; Delincé P
    J Bone Joint Surg Br; 2006 Jan; 88(1):116-8. PubMed ID: 16365133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone morphogenetic protein-2 for the treatment of congenital pseudarthrosis of the tibia or persistent tibial nonunion in children and adolescents: A retrospective study with a minimum 2-year follow-up.
    Hissnauer TN; Stiel N; Babin K; Rupprecht M; Hoffmann M; Rueger JM; Stuecker R; Spiro AS
    J Mater Sci Mater Med; 2017 Apr; 28(4):60. PubMed ID: 28213747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series.
    Spiro AS; Babin K; Lipovac S; Stenger P; Mladenov K; Rupprecht M; Rueger JM; Stuecker R
    J Bone Joint Surg Br; 2011 May; 93(5):695-9. PubMed ID: 21511938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice.
    Schindeler A; Ramachandran M; Godfrey C; Morse A; McDonald M; Mikulec K; Little DG
    J Orthop Res; 2008 Jan; 26(1):65-74. PubMed ID: 17787010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. rhBMP-2 (ACS and CRM formulations) overcomes pseudarthrosis in a New Zealand white rabbit posterolateral fusion model.
    Lawrence JP; Waked W; Gillon TJ; White AP; Spock CR; Biswas D; Rosenberger P; Troiano N; Albert TJ; Grauer JN
    Spine (Phila Pa 1976); 2007 May; 32(11):1206-13. PubMed ID: 17495777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of congenital pseudarthrosis of the tibia with the Ilizarov method in a paediatric population: influence of aetiological factors.
    Borzunov DY; Chevardin AY; Mitrofanov AI
    Int Orthop; 2016 Feb; 40(2):331-9. PubMed ID: 26546064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distal tibial fracture repair in a neurofibromatosis type 1-deficient mouse treated with recombinant bone morphogenetic protein and a bisphosphonate.
    Schindeler A; Birke O; Yu NY; Morse A; Ruys A; Baldock PA; Little DG
    J Bone Joint Surg Br; 2011 Aug; 93(8):1134-9. PubMed ID: 21768643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congenital pseudarthrosis of neurofibromatosis type 1: impaired osteoblast differentiation and function and altered NF1 gene expression.
    Leskelä HV; Kuorilehto T; Risteli J; Koivunen J; Nissinen M; Peltonen S; Kinnunen P; Messiaen L; Lehenkari P; Peltonen J
    Bone; 2009 Feb; 44(2):243-50. PubMed ID: 19061981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of a congenital pseudarthrosis of the tibia by osteogenic protein-1 (bone morphogenetic protein-7): a case report.
    Anticevic D; Jelic M; Vukicevic S
    J Pediatr Orthop B; 2006 May; 15(3):220-1. PubMed ID: 16601593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications.
    Khan SN; Lane JM
    Expert Opin Biol Ther; 2004 May; 4(5):741-8. PubMed ID: 15155165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sinus augmentation using rhBMP-2/ACS in a mini-pig model: relative efficacy of autogenous fresh particulate iliac bone grafts.
    Lee J; Susin C; Rodriguez NA; de Stefano J; Prasad HS; Buxton AN; Wikesjö UM
    Clin Oral Implants Res; 2013 May; 24(5):497-504. PubMed ID: 22276816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pivotal, randomized, parallel evaluation of recombinant human bone morphogenetic protein-2/absorbable collagen sponge and autogenous bone graft for maxillary sinus floor augmentation.
    Triplett RG; Nevins M; Marx RE; Spagnoli DB; Oates TW; Moy PK; Boyne PJ
    J Oral Maxillofac Surg; 2009 Sep; 67(9):1947-60. PubMed ID: 19686934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone morphogenetic protein (RhBMP-2) as a substitute for iliac crest bone graft in multilevel adult spinal deformity surgery: minimum two-year evaluation of fusion.
    Mulconrey DS; Bridwell KH; Flynn J; Cronen GA; Rose PS
    Spine (Phila Pa 1976); 2008 Sep; 33(20):2153-9. PubMed ID: 18725869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No advantage to rhBMP-2 in addition to autogenous graft for fracture nonunion.
    Takemoto R; Forman J; Taormina DP; Egol KA
    Orthopedics; 2014 Jun; 37(6):e525-30. PubMed ID: 24972432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.